Favourable behavioural actions of RGH-188, a novel dopamine D3/D2 receptor antagonist/partial agonist antipsychotic candidate

被引：0
|
作者：
Gyertyan, I. [1 ]
Kiss, B. [1 ]
Saghy, K. [1 ]
Laszy, J. [1 ]
Szabo, G. [1 ]
Agai-Csongor, E. [1 ]
Domany, G. [1 ]
Tihanyi, K. [1 ]
Szombathelyi, Z. [1 ]
机构：
[1] Pharmacol & Drug Safety Res, Budapest, Hungary
来源：
BEHAVIOURAL PHARMACOLOGY | 2007年 / 18卷
关键词：
D O I：
暂无
中图分类号：
B84 [心理学]; C [社会科学总论]; Q98 [人类学];
学科分类号：
03 ; 0303 ; 030303 ; 04 ; 0402 ;
摘要：
引用
收藏
页码：S12 / S13
页数：2
相关论文
共 50 条
  • [41] TAK-906, A NOVEL DOPAMINE D2/D3 RECEPTOR ANTAGONIST FOR THE TREATMENT OF GASTROPARESIS
    Whiting, Roger
    Choppin, Agnes
    Luehr, Gary
    GASTROENTEROLOGY, 2020, 158 (06) : S638 - S639
  • [42] The novel atypical antipsychotic cariprazine demonstrates dopamine D2 receptor-dependent partial agonist actions on rat mesencephalic dopamine neuronal activity
    Delcourte, Sarah
    Ashby, Charles R., Jr.
    Rovera, Renaud
    Kiss, Bela
    Adham, Nika
    Farkas, Bence
    Haddjeri, Nasser
    CNS NEUROSCIENCE & THERAPEUTICS, 2018, 24 (12) : 1129 - 1139
  • [43] Functionally Selective Dopamine D2, D3 Receptor Partial Agonists
    Moeller, Dorothee
    Kling, Ralf C.
    Skultety, Marika
    Leuner, Kristina
    Huebner, Harald
    Gmeiner, Peter
    JOURNAL OF MEDICINAL CHEMISTRY, 2014, 57 (11) : 4861 - 4875
  • [44] Aripiprazole, a novel antipsychotic, is a potent partial agonist at human dopamine D2 receptors
    Burris, KD
    Molski, TF
    Ryan, E
    Xu, C
    Tottori, K
    Kikuchi, T
    Yocca, FD
    Molinoff, PB
    SCHIZOPHRENIA RESEARCH, 2001, 49 (1-2) : 88 - 88
  • [45] Antiparkinsonian effects of the novel D3/D2 dopamine receptor agonist, S32504, in MPTP-lesioned marmosets:: Mediation by D2, not D3, dopamine receptors
    Hill, Michael P.
    Ravenscroft, Paula
    McGuire, Steven G.
    Brotchie, Jonathan M.
    Crossman, Alan R.
    Rochat, Catherine
    Millan, Mark J.
    MOVEMENT DISORDERS, 2006, 21 (12) : 2090 - 2095
  • [46] Antidepressant effects of pramipexole, a dopamine D3/D2 receptor agonist, and 7-OH-DPAT, a dopamine D3 receptor agonist, in olfactory bulbectomized rats
    Breuer, Megan E.
    Groenink, Lucianne
    Oosting, Ronald S.
    Buerger, Erich
    Korte, Michiel
    Ferger, Boris
    Olivier, Berend
    EUROPEAN JOURNAL OF PHARMACOLOGY, 2009, 616 (1-3) : 134 - 140
  • [47] Pharmacology of the atypical antipsychotic remoxipride, a dopamine D2 receptor antagonist
    Nadal, R
    CNS DRUG REVIEWS, 2001, 7 (03): : 265 - 282
  • [48] Process Development of an Efficient Kilogram-Scale Preparation of a Preferential Dopamine D3 versus D2 Receptor Antagonist SIPI 6398 as a New Antipsychotic Candidate
    Zhou, Ai-Nan
    Chen, Xiao-Wen
    Qj, Yang-Li
    Duan, Geng-Li
    Li, Jian-Qi
    ORGANIC PROCESS RESEARCH & DEVELOPMENT, 2019, 23 (07) : 1442 - 1449
  • [49] Dopamine D2/D3 receptor availability and venturesomeness
    Bernow, Nina
    Yakushev, Igor
    Landvogt, Christian
    Buchholz, Hans-Georg
    Smolka, Michael N.
    Bartenstein, Peter
    Lieb, Klaus
    Gruender, Gerhard
    Vernaleken, Ingo
    Schreckenberger, Mathias
    Fehr, Christoph
    PSYCHIATRY RESEARCH-NEUROIMAGING, 2011, 193 (02) : 80 - 84
  • [50] F15063, a novel antipsychotic with dopamine D2/D3 antagonist, 5-HT1A agonist and D4 partial agonist properties:: III.: Duration of brain D2-like receptor occupancy, antipsychotic-like activity and plasma concentration in rodents
    Assie, M. B.
    Bardin, L.
    Auclair, A. L.
    Consul-Denjean, N.
    Sautel, E.
    Kleven, M. S.
    Depoortere, R.
    Newman-Tancredi, A.
    EUROPEAN NEUROPSYCHOPHARMACOLOGY, 2006, 16 : S432 - S433
12345